Monday, January 20, 2020 Breaking news - Decision in case T 844/18 on the CRISPR gene editing technology

Last week, oral proceedings took place in T 844/18 on the CRISPR gene editing technology and a decision was taken at the end of the oral proceedings. On Friday, the news message below was posted on the EPO website.

Wednesday, April 17, 2019 T 0725/14 - Valid transfer of rights results in invalid priority claim

If during the priority year a European patent application - filed by applicant A - is transferred to a party B, is then the priority claim from a subsequent application (from which the patent in suit matured) by applicant A to the earlier application valid? Which acts and statements, including their timing, constitute the transfer of a priority right between parties? And what role do the parties' intentions - as far as they can be derived from the documents on file - play in this?

Tuesday, May 29, 2018 EP2771468 - Decision of OD in Crispr case (first instance)

You can't slice up a priority right

Today we have the  first instance decision in the opposition against European patent 2771468 having the title "ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION" (PCT/US13/74819). The grounds for the decision were published 26 March 2018.


We usually only have  board of appeal decisions, but I'm told this is an important case as it relates to the CRISPR technique of DNA manipulation. It is moreover interesting because of its scale and the issues it raises. There were 9 opponents, 255 documents filed, 72 auxiliary request and a 40-page decision.

The priority documents are US provisionals and each have a number of natural persons as inventors/applicants. I count a total of 12 different natural persons who are applicants to the priority documents in various combinations. It turns out that for some of these persons the priority rights had not been transferred to an applicant of the PCT application, or at least evidence of a transfer acceptable to the OD was not filed.  As a result, the priority claim was objected to the by the opponents. The proprietors have numerous arguments why this objection should not be allowed, but in the end the priority claim is not accepted. Because of the invalid priority, the patent was found not novel.

The underlying problem appears to be hidden in reasons 75-75.1: one of the inventor/applicants of the provisional was not an inventor in the sense of the US law. Accordingly, his successor in title was left of the PCT application, probably to satisfy US law. That one of the persons, who is not an inventor, misses as an applicant on the PCT application now appears to doom this patent in Europe.

Notice of appeal has already been filed, so we'll be interested to see how this case progresses.  

Friday, September 01, 2017 T 1519/15 - Not so poisonous parent

A 'family' of Amanita muscaria, which is best not eaten

This Examination Appeal shows the Board applying G 1/15 to what would otherwise have been a 'poisonous parent' situation. The outcome is as expected - the decision under appeal is set aside.

The Examination Division considered , pre-G 1/15, the situation as follows: claim 1 of the divisional application represents a generalization with respect to a species described in an earliest US priority document P1, and thus is, in accordance with the pre-G/15 legal situation, in its entirety entitled only to a later priority date from a US priority document P2. The EP parent application, which is cited as D3, also describes P1's species and is thus, at least in as far as pertaining to this species, entitled to the earliest priority date P1. D3 thus belongs, at least in as far as the described species, to the Art. 54(3) State of the Art of the divisional application and thus takes away the novelty of claim 1.

Friday, September 11, 2015 T 1155/11: the Board introduces a new document - unravelling a web of priority claims

 

The Board of appeal introduced an additional document that was not mentioned before in the Examination procedure. I didn't see this before and I was surprised. The Board writes in its "Communication of the Board" (dated 3/2/15, sent to the appellant (applicant) together with the invitation to attend oral proceedings):
"The Board notes that in addition to D1 and D2, there are several European patent applications from the same applicant describing subject-matter very close to that of the present application. [...] At least some of those European patent applications have earlier priorities than the second priority date of the present application, 16 April 2003, and describe similar subject-matter. Such applications may be relevant under Article 54(3) EPC in case the first priority date is found to be invalid or to cover only part of the claimed subject—matter."
Subsequently a new document D9 is introduced in the proceedings which claims priority from three priority documents and one of these documents is also a priority application of the patent application that is subject of this Appeal. It seems that, in this decision, the Board tries to unravel the web formed by multiple applications of the same Applicant that claim priority of a multitude of priority applications.
In this decision the subsequent priority claims are relevant:
The patent application that is subject of this appeal is filed on 1 Oct 2003 and claims priority from Korean priority patent application P1 of 17 Feb 2003 and P2 of 16 Apr 2003.
Document D9 (EP1573723), as introduced by the Board, is filed on 1 Oct 2003 and claims priority from Korean priority patent application P3 of 21 Feb 2003, P4 of 3 Mar 2003 and also of P2 of 16 Apr 2003.
If the priority claim from P1 for some of the features of the amended claims from P1 is not valid, and these features are described in D9 and also in one of P3 and P4, then document D9 is an Art. 54(3) EPC document for the amended claims. In the decision a certified translation of P4 and P2 is introduced in the proceedings as respective documents D10 and D11.